SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Brendon L. Neuen(The George Institute for Global Health), Meg Jardine(Royal North Shore Hospital), Vlado Perkovic(New South Wales Department of Health), Hiddo J.L. Heerspink(University Medical Center Groningen), Séverine Bompoint(Royal North Shore Hospital), Laurent Billot(The George Institute for Global Health), Clare Arnott(Royal Prince Alfred Hospital), Adeera Levin(University of British Columbia), David C. Wheeler(University College London), Bruce Neal(UNSW Sydney), David M. Charytan(NYU Langone Health), Kenneth W. Mahaffey(Cardiovascular Institute of the South), T. Kue Young(The George Institute for Global Health)
The Lancet Diabetes & Endocrinology
September 5, 2019
10.1016/s2213-8587(19)30256-6
Cited by 870

Related Papers

K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k